Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2019

Jul 31, 2019

SELL
$4.1 - $8.05 $44,431 - $87,237
-10,837 Closed
0 $0
Q1 2019

May 03, 2019

SELL
$5.41 - $8.73 $108,492 - $175,071
-20,054 Reduced 64.92%
10,837 $89,000
Q4 2018

Feb 06, 2019

BUY
$5.39 - $9.15 $166,502 - $282,652
30,891 New
30,891 $171,000

Others Institutions Holding AKBA

About Akebia Therapeutics, Inc.


  • Ticker AKBA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 183,848,992
  • Market Cap $305M
  • Description
  • Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...
More about AKBA
Track This Portfolio

Track Stevens Capital Management LP Portfolio

Follow Stevens Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stevens Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Stevens Capital Management LP with notifications on news.